Gene therapy for colorectal cancer
OwnerMin-Chuan Huang, Hsiao-Yu Cheninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the novel use of a core 2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) in the treatment of colorectal cancer. Accordingly, the present invention provides a method for treating colorectal cancer in a subject including administering to the subject a nucleic acid molecule including a sequence encoding C2GnT, wherein the sequence is expressed in cancer cells. The present invention also provides a pharmaceutical composition for treating colorectal cancer including a nucleic acid molecule including a sequence encoding C2GnT, and a pharmaceutically acceptable carrier.
Claims19
A method for treating colorectal cancer in a subject comprising administering to the subject a nucleic acid molecule comprising a sequence encoding C2GnT, wherein C2GnT exhibits core 2 branching enzyme activity on O-glycans.
A pharmaceutical composition for treating colorectal cancer comprising a nucleic acid molecule comprising a sequence encoding C2GnT, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.